Chiquita Brooks-LaSure, Centers for Medicare and Medicaid Services administrator (Evan Vucci/AP Images)

Whoops: CMS qui­et­ly pares back list of drugs re­quir­ing new re­bates un­der In­fla­tion Re­duc­tion Act

To dis­cour­age rapid drug price in­creas­es, the In­fla­tion Re­duc­tion Act re­quires phar­ma com­pa­nies that raise cer­tain drug prices faster than the rate of in­fla­tion to pay Medicare new re­bates, be­gin­ning in 2025.

But the ini­tial list of 27 drugs that would be hit with the re­bates, un­veiled March 15, was cut by about 25% late last week, with CMS now re­mov­ing sev­en of those drugs, in­clud­ing two from Gilead.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.